ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd.

Overview
Date Founded

1989

Headquarters

Vancouver Island Technology Park,Markham Street,Unit 3204-4464,Victoria, BC V8Z 7X8

Type of Company

Public

Industries

Biotechnology

Company Description

ImmunoPrecise Antibodies Ltd. engages in the provision of integrated antibody solutions. It services include human monoclonals, hybridoma development, rabbit monoclonals, b-cell select, phage display, cryostorage, hybridoma sequencing, antibody generation, anti-body purification, polyclonal production, and peptide production. The company was founded by Robert Beecroft in 1989 and is headquartered in Victoria, Canada.

Executives & Employees

Founder

President, Chief Executive Officer & Director

Chief Financial Officer

Chief Technology Officer

General Manager

Vice President, Client Relations & Project Management

Chief Business Officer

Director, Molecular Services

Senior Scientist & Director of Hybridoma Services

Senior Scientific Leader

Board of Directors

Chief Executive Officer & President at Brisio Innovations, Inc.

President & Director at Omega Mechanical Ltd.

President, Chief Executive Officer & Director at ImmunoPrecise Antibodies Ltd.

Founder at ImmunoPrecise Antibodies Ltd.

Vice President at Ligand Pharmaceuticals, Inc.

Professor-Emeritus at University of Victoria

Paths to ImmunoPrecise Antibodies Ltd.
Potential Connections via
Relationship Science
You
ImmunoPrecise Antibodies Ltd.
Recent Transactions
Details Hidden

ImmunoPrecise Antibodies Ltd. raised money in a private placement transaction

Details Hidden

ImmunoPrecise Antibodies Ltd. raised money in a private placement transaction

Details Hidden

ImmunoPrecise Antibodies Ltd. purchases Preclinics GmbH

Advisors & Consultants
Publicist

President, Chief Executive Officer & Director at Avanti Energy, Inc.

Key Stats and Financials As of 2019
Market Capitalization
$37.1M
Total Enterprise Value
$46.4M
Earnings Per Share
$-0.12
Revenue
$10.9M
Net Profit
$-7.62M
EBITDA
$-3.96M
EBITDAMargin
-36.28%
Total Debt
$2.93M
Total Equity
$18.1M
Enterprise Value Sales
4.24x
TEVNet Income
-6.09x
Debt TEV
0.06x
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by ImmunoPrecise Antibodies Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of ImmunoPrecise Antibodies Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and ImmunoPrecise Antibodies Ltd..